February 13, 2018 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that it has completed construction and taken occupancy of Building One, the first building of the SHINE medical isotope production campus.
After breaking ground in August of 2017, JP Cullen completed the 6-month construction project three weeks ahead of schedule and on budget, with zero OSHA-recordable incidents. The 11,400 sq. ft. Building One will be one of the most advanced, private, nuclear technology facilities in the world. Buildout inside the building is starting now and during summer 2018 the facility will be used to house the first integrated, full-size SHINE production system. During construction of SHINE’s main production facility, Building One will be used to train employees and develop operating history with equipment. Going forward, Building One will be a state-of-the-art technology development center.
“Building One’s name was chosen because it’s intended to be a technological genesis building,” said Greg Piefer, founder and CEO of SHINE. “It will be a laboratory in which we continue to develop new technologies to keep SHINE at the forefront of medical isotope production and nuclear innovations beyond that.”
The completion of Building One comes as the company prepares to break ground on its main production facility in Janesville, Wisconsin, after receiving its construction permit from the U.S. Nuclear Regulatory Commission in 2016. The SHINE facility will produce molybdenum-99 and other medical isotopes used to detect and treat a wide variety of diseases, including heart disease and cancer.
Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including Mo‑99.
Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth. Want to learn more about SHINE? Follow us on social media @shinefusion and sign up for our email newsletter to follow us on our journey!
Media Contact: info@shinefusion.com
